Journal of Obesity & Weight Loss Therapy
Open Access

Endocrine; Immune checkpoint inhibitors; Diagnostic approaches; Clinical management; Side effects; Treatment options

Introduction

The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment [1,2], offering new hope for patients with various malignancies. While these therapies have shown remarkable efficacy in enhancing antitumor immune responses, they are not without their challenges. One significant issue that has emerged is the development of endocrine complications, which can range from thyroid dysfunction to adrenal insufficiency and beyond. Understanding and managing these endocrine side effects are crucial for optimizing patient care and treatment outcomes. Early detection and appropriate intervention can prevent serious complications and allow patients to continue benefiting from ICI therapy. This article aims to provide a comprehensive guide on diagnosing and managing endocrine complications associated with ICIs. We will discuss the clinical presentation [3], diagnostic procedures, and treatment strategies tailored to address these specific challenges. By equipping healthcare professionals with this knowledge, we hope to improve the quality of care for patients receiving immune checkpoint inhibitor therapy.

Materials and Methods

This review is structured as a comprehensive analysis of existing literature, clinical guidelines, and expert recommendations on the management of endocrine complications induced by immune checkpoint inhibitors [4]. A systematic literature search was conducted using electronic databases such as PubMed, Embase, and Cochrane Library. Keywords including endocrine complications, immune checkpoint inhibitors, diagnosis, clinical management, side effects, and treatment were used to identify relevant articles, reviews, and guidelines published up to January 2022. Studies and articles were included if they provided insights into the diagnosis, management, or treatment of endocrine side effects associated with immune checkpoint inhibitors. Both clinical trials and observational studies were considered.

Information extracted from the selected studies included study design, patient demographics, types of immune checkpoint inhibitors used, endocrine complications reported, diagnostic methods employed, and treatment strategies implemented [5,6]. Data were analyzed to identify common trends, challenges, and recommendations related to the diagnosis and management of endocrine complications induced by immune checkpoint inhibitors. The findings were then synthesized to provide practical guidelines and recommendations for healthcare professionals. As this is a review of existing literature and guidelines, ethical approval was not required. However, all information was handled with confidentiality and in accordance with relevant data protection regulations. While every effort was made to include comprehensive and up-to-date information, the review is limited by the available literature and may not capture all recent developments or individual case reports. By employing this methodological approach, we aim to offer a robust and evidence-based overview of the current understanding and management of endocrine complications caused by immune checkpoint inhibitors.

Results and Discussion

Numerous studies have reported varying rates of endocrine complications associated with immune checkpoint inhibitors [7,8]. Thyroid dysfunction, including hypothyroidism and hyperthyroidism, appears to be the most common, followed by adrenal insufficiency and less frequently, hypophysitis and diabetes mellitus. The diagnosis of endocrine side effects often relies on clinical symptoms, coupled with laboratory testing. Thyroid function tests, cortisol levels, and additional hormone assays are commonly employed for early detection. Imaging studies such as MRI or CT scans may also be used to assess glandular involvement in more complex cases. Management of endocrine complications requires a multidisciplinary approach involving endocrinologists, oncologists, and other specialists. Treatment options often include hormone replacement therapy, immunosuppressive agents, or discontinuation of the offending immune checkpoint inhibitor, depending on the severity and type of complication [9]. Managing endocrine complications can be challenging due to the variability in clinical presentation and the potential for overlap with other conditions. Additionally, the optimal duration of treatment and the potential for long-term endocrine dysfunction remain areas of ongoing research and debate.

The development of endocrine complications from immune checkpoint inhibitors underscores the importance of vigilant monitoring and timely intervention. Early recognition and management are crucial for minimizing morbidity and optimizing treatment outcomes. The variability in the presentation and severity of endocrine side effects necessitates individualized treatment approaches. Regular monitoring of hormone levels and clinical symptoms is essential for assessing treatment response and adjusting therapy as needed. Furthermore, ongoing research is needed to better understand the underlying mechanisms of endocrine dysfunction induced by immune checkpoint inhibitors and to develop targeted interventions that minimize these side effects without compromising antitumor efficacy [10]. In conclusion, while immune checkpoint inhibitors offer significant therapeutic benefits, they also carry the risk of inducing endocrine complications. Through diligent monitoring, early diagnosis, and multidisciplinary management, healthcare professionals can effectively mitigate these risks and improve the overall care of patients receiving immune checkpoint inhibitor therapy.

Conclusion

Endocrine complications induced by immune checkpoint inhibitors represent a significant clinical challenge in oncology practice. While these therapies have transformed cancer treatment and improved patient outcomes, they also carry the potential for disrupting endocrine function, leading to a range of complications from thyroid dysfunction to adrenal insufficiency. Vigilant monitoring and early intervention are paramount in managing these complications effectively. Healthcare professionals must be aware of the signs and symptoms of endocrine dysfunction and be prepared to employ appropriate diagnostic tests and treatment strategies promptly.

Multidisciplinary collaboration among endocrinologists, oncologists, and other specialists is essential for delivering comprehensive care tailored to each patient's needs. Individualized treatment plans, based on the type and severity of endocrine side effects, can help optimize outcomes while minimizing morbidity. Ongoing research and clinical trials are crucial for advancing our understanding of the underlying mechanisms of endocrine complications and developing targeted interventions. Future efforts should focus on identifying predictive markers, refining treatment algorithms, and exploring novel therapeutic approaches to mitigate the risks associated with immune checkpoint inhibitor therapy. In summary, while the emergence of endocrine complications is a recognized downside of immune checkpoint inhibitors, proactive management strategies and ongoing research offer hope for improving the safety and effectiveness of these groundbreaking therapies. With continued vigilance and collaboration, healthcare professionals can navigate these challenges and continue to enhance the quality of care for patients with cancer.

Acknowledgement

None

Conflict of Interest

None

References

1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32: 1335-1343.

Indexed at, Google Scholar, Crossref

2. Yoo MJ, Long B, Brady WJ, Holian A, Sudhir A, et al. (2021) Immune checkpoint inhibitors: an emergency medicine focused review. Am J Emerg Med 50: 335-344.

Indexed at, Google Scholar, Crossref

3. Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, et al. (2019) Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. BMC Endocr Disord 19: 144.

Indexed at, Google Scholar, Crossref

4. Puls HA, Haas NL, Franklin BJ, Theyyunni N, Harvey CE, et al. (2021) Euglycemic diabetic ketoacidosis associated with SGLT2i use: case series. Am J Emerg Med 44: 11-13.

Indexed at, Google Scholar, Crossref

5. Godwin Jl, Jaggi S, Sirisena I, Sharda P, Rao AD, et al. (2017) Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunothe Cancer 5: 40.

Indexed at, Google Scholar, Crossref

6. Kotwal A, Haddox C, Block M, Yogish C, Kudva YC, et al. (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res and Care 7: e000591.

Indexed at, Google Scholar, Crossref

7. Mae S, Kuriyama A, Tachibana H (2021) Diabetic ketoacidosis as a delayed immune-related event after discontinuation of nivolumab. J Emerg Med 60: 342-344.

Indexed at, Google Scholar, Crossref

8. Haas NL, Gianchandani RY, Gunnerson KJ, Bassin BS, Ganti A, et al. (2018) The two-bag method for treatment of diabetic ketoacidosis in adults. J Emerg Med 54: 593-599.

Indexed at, Google Scholar, Crossref

9. Nikouline A, Brzozowski M (2021) New DKA in a geriatric patient on immune checkpoint inhibitor therapy: a case report. CJEM 23: 712-714.

Indexed at, Google Scholar, Crossref

10. Maamari J, Yeung SCJ, Chaftari PS (2019) Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am J Emerg Med 37: 376.

Indexed at, Google Scholar, Crossref